Myocarditis Following Immune Checkpoint Inhibition With Pembrolizumab: Management in a Context of Steroid IntoleranceNovel Teaching Points
Immune checkpoint inhibitors (ICIs) are a major advance in oncology and have become first- or second-line therapy for over 50% of oncology patients. ICI-associated myocarditis is a complication that, although rare, has a high mortality rate. We present a case of ICI-associated myocarditis presenting...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-10-01
|
| Series: | CJC Open |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589790X22001287 |